Analysis of in vitro and in vivo sensitivity of oral cancer cells to methotrexate
Aim: The present study was directed on the assessment of the response of treatment-naive oral cancer cells to methotrexate (MTX) in vitro and clinical response to MTX therapy. Methods: A pilot study of in vitro evaluation of MTX response of oral cancer cells from 10 patients was conducted using a...
Збережено в:
Дата: | 2009 |
---|---|
Автори: | , , , , , |
Формат: | Стаття |
Мова: | English |
Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2009
|
Назва видання: | Experimental Oncology |
Теми: | |
Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/135717 |
Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
Цитувати: | Analysis of in vitro and in vivo sensitivity of oral cancer cells to methotrexate / R.B. Pai, R.M. Lalitha, S.B. Pai, S.V. Kumaraswamy, N. Lalitha, M.K. Bhargava // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 118–120. — Бібліогр.: 14 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of UkraineРезюме: | Aim: The present study was directed on the assessment of the response of treatment-naive oral cancer cells to methotrexate (MTX)
in vitro and clinical response to MTX therapy. Methods: A pilot study of in vitro evaluation of MTX response of oral cancer cells
from 10 patients was conducted using a cell viability assay to determine the sensitivity/resistance to MTX. Quantitative in vitro data
were correlated to the clinical outcome to MTX therapy. Results: A positive correlation was observed between the effect of MTX
on tumor cells in vitro and clinical response for 7 out of 10 patients. Conclusions: Observations from the proof-of-principle pilot
study suggests that oral cancer cells have intrinsically variable response toMTX. Confirmation ofthese findings with a larger cohort
of patients could aid in the development of individualized therapies for this class of malignancy. |
---|